Ultralife (NASDAQ:ULBI) reported quarterly sales of $36.11 million which missed the analyst consensus estimate of $37.00 million by 2.41 percent. This is a 51.95 percent increase over sales of $23.76 million the same period last year.
Exelixis And Arcus Biosciences Announce Clinical Trial Collaboration To Evaluate Zanzalintinib In Combination With AB521 In Patients With Advanced Renal Cell Carcinoma
– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 –Exelixis, Inc. (NASDAQ:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have entered into a clinical trial
